Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin in Elderly DLBCL (POLAR BEAR)
NCT04332822Phase 3Recruiting
- Sponsor
- Nordic Lymphoma Group
- Start
- Aug 2020
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
A Phase 3 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Nordic Lymphoma Group. Started Aug 2020; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04332822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332822.